A recent study found higher mutation rates in the gene encoding activin A receptor type 2A among patients with nonalcoholic steatohepatitis (NASH)-associated HCC than among patients with HCC due to other etiologies (10% vs. 3%, p<0.05). This evidence concerns the gene ACVR2A and hepatocellular carcinoma.